CAMBRIDGE, Mass., June 25, 2025 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage biotechnology company transforming the treatment of autoimmune diseases, today announced that it has ...

Shares of Vor Bio are up 120% in pre-market trade on Thursday. For More Such Health News, visit rttnews.com. The views and opinions expressed herein are the views and opinions of the author and do ...

Vor Bio is licensing global rights to a fusion protein that inhibits two targets to potentially treat the neuromuscular disorder generalized myasthenia gravis. It’s a pivot for Vor, which last ...

Vor Biopharma shares surge 43% after licensing deal, $175M raise, and CEO transition.

A number of major brands have scaled back their visible support of high-profile Pride Month events this year, while others are withdrawing their sponsorships entirely, even as their internal ...

Clarke Schmidt has been thriving lately by leaning into the art of pitching and using his entire arsenal.

RFK Jr.’s Vaccine Panel Has a New Approach: Question Everything Immunizations ‘are not all good or bad,’ says the chair of the overhauled committee By Liz Essley Whyte Share ...

Chief Executive Officer of the Financial Services Commission (FSC) Warrick Ward has called for a more collaborative and forward-looking approach to insurance regulation as the region grapples with ...

By Natalie Weger Vor Biopharma named Sandy Mahatme as chief financial officer and chief business officer, effective July 9.

Now in its sixth month, President Trump's administration has become the antithesis of progress, many LGBTQ Americans say.

Arsenal make formal contact with Chelsea over the potential signing of England winger Noni Madueke.